

A Myc-Slug (Snail2)/Twist regulatory circuit directs vascular development

Claudia O. Rodrigues^{1,2}, Steve T. Nerlick³, Elsie L. White¹, John L. Cleveland^{1,4,*} and Mary Lou King^{3,*}

Myc-deficient mice fail to develop normal vascular networks and *Myc*-deficient embryonic stem cells fail to provoke a tumor angiogenic response when injected into immune compromised mice. However, the molecular underpinnings of these defects are poorly understood. To assess whether *Myc* indeed contributes to embryonic vasculogenesis we evaluated *Myc* function in *Xenopus laevis* embryogenesis. Here, we report that *Xc-Myc* is required for the normal assembly of endothelial cells into patent vessels during both angiogenesis and lymphangiogenesis. Accordingly, the specific knockdown of *Xc-Myc* provokes massive embryonic edema and hemorrhage. Conversely, *Xc-Myc* overexpression triggers the formation of ectopic vascular beds in embryos. *Myc* is required for normal expression of *Slug/Snail2* and *Twist*, and either *XSlug/Snail2* or *XTwist* could compensate for defects manifest by *Xc-Myc* knockdown. Importantly, knockdown of *Xc-Myc*, *XSlug/Snail2* or *XTwist* within the lateral plate mesoderm, but not the neural crest, provoked embryonic edema and hemorrhage. Collectively, these findings support a model in which *Myc*, *Twist* and *Slug/Snail2* function in a regulatory circuit within lateral plate mesoderm that directs normal vessel formation in both the vascular and lymphatic systems.

KEY WORDS: *Myc*, *Slug/Snail2*, *Twist*, Vasculogenesis, Lymphangiogenesis, *Xenopus*

INTRODUCTION

Myc, and its closest family members N-*myc* (*Mycn*) and L-*Myc*, function as basic helix-loop-helix/leucine zipper transcription factors that regulate diverse cellular responses and are commonly activated in cancer (Nesbit et al., 1999; Grandori et al., 2000). Under normal conditions, the transcription of *Myc* genes is mitogen dependent and is suppressed by growth inhibitory signaling pathways and by the tumor suppressors p53 and pRb (Grandori et al., 2000; Bernard and Eilers, 2006). The pervasive selection for *Myc* overexpression in cancer reflects its pivotal roles in regulating progression through the cell cycle (Roussel et al., 1991), increases in cell mass (Iritani and Eisenman, 1999) and the tumor angiogenic response (Pelengaris et al., 1999; Baudino et al., 2002; Knies-Bamforth et al., 2004).

Loss-of-function experiments have revealed a conserved role for *Myc* in regulating cell growth and division in both vertebrates and invertebrates. For example, in *Drosophila* mosaic *dmvc* (*dm* – FlyBase) mutants, the wing discs grow very poorly, are smaller in size and are out-competed by wild-type cells (Johnston et al., 1999). Furthermore, the conditional knockout of *Myc* in mice established its essential role in the G1- to S-phase transition of the cell cycle (de Alboran et al., 2001; Trumpf et al., 2001). However, there are also obvious consequences of *Myc* loss on developmental processes. For example, the conditional deletion of *Myc* in the hematopoietic compartment leads to an accumulation of hematopoietic stem cells that fail to migrate from the bone marrow (Wilson et al., 2004) and *Myc* loss in the mouse leads to stunted growth, neural tube closure defects and pericardial swelling, and to profound defects in embryonic vasculogenesis, angiogenesis and hematopoiesis (Davis et al., 1993; Trumpf et al., 2001; Baudino et al., 2002).

The broad and devastating effects of *Myc* loss on mouse embryonic development suggested that many might be attributed to hematopoietic failure, and/or to defects of *Myc*^{−/−} embryos in vasculogenesis (Baudino et al., 2002). Indeed, mouse embryos haploinsufficient for the angiogenic cytokine vascular endothelial growth factor (*Vegf*) (Carmeliet et al., 1996; Ferrara et al., 1996) or its receptors *Flt1* (*VegfR1*) (Fong et al., 1995) or *Flk1* (*Kdr* – Mouse Genome Informatics) (Shalaby et al., 1995) display phenotypes that are similar to those manifest by the *Myc* knockout. Furthermore, *Myc* is expressed in endothelial-like progenitors of the blood islands that are known to give rise to the primitive vascular and hematopoietic system, and *Myc*-deficient cells have defects in the expression of angiogenic regulators (Baudino et al., 2002).

Although the defects in vascular development in the mouse *Myc* knockout suggested this was a cause of lethality, the failure of these embryos could also be due to placental defects. *Xenopus laevis* is a tractable model system that lacks this concern and allows the analysis of pathways that control cell fate decisions during early embryogenesis. More importantly, the vascular system of the *Xenopus* embryo is easily visualized and is very similar to that of higher vertebrates (Levine et al., 2003; Ny et al., 2005). Furthermore, these embryos can survive without a circulatory system for an extended time, permitting mutants to be analyzed well into development (Mohun et al., 2000). Indeed, here we report that specific knockdown of *Xc-Myc* in post-gastrulation stages does not lead to defects in embryonic hematopoiesis or vasculogenesis per se, but rather leads to defects in the maturation and completion of vessel development in both the vascular and lymphatic systems. Importantly, these defects were rescued by the transcription factors *Twist* and/or *Slug* (also known as *Snail2*), indicating that a *Myc*-*Twist*/*Slug* circuit is required to direct and complete normal vessel development.

MATERIALS AND METHODS

Morpholino oligonucleotides, plasmids and mRNA

To knockdown *Xc-Myc* expression, we designed a morpholino oligonucleotide (Gene-Tools), Mo I (5'-CATCTTCTGCGATGCGAT-TGGTC) to target *Xc-Myc1* transcripts, which are expressed throughout

¹Department of Biochemistry, St Jude Children's Research Hospital, Memphis, TN 38105, USA. ²Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL, USA. ³Department of Cell Biology, University of Miami Miller School of Medicine, Miami, FL, USA. ⁴Department of Cancer Biology, The Scripps Research Institute-Florida, Jupiter, FL 33458, USA.

* Authors for correspondence (e-mails: jcleve@scripps.edu; mking@med.miami.edu)

embryonic development (see Fig. S1 in the supplementary material). A standard, commercially available control morpholino (5'-CCTCTT-ACCTCAGTTACAATTATA) and a scrambled *Xc-Myc* morpholino (5'-CGATAATTGCGGTTAACAGGCATGT) with five mismatches (in bold) were used in this study. For rescue experiments, the *Xc-Myc* cDNA was used to generate a construct (*Xc-Myc-Mut*) in which the morpholino recognition region was mutated by site-directed mutagenesis using the Stratagene Quick Change Site-directed Kit. Mutations were confirmed by sequencing. Morpholino oligos designed to target *XSlug* (5'-TCTTGACCAGAA-AAGAGCGTGGCAT) and *XTwist* (5'-TGGACTCTTCCTGCATCA-TTTTCT) were obtained from Gene-Tools. *XSlug* and *XTwist* were cloned into the pGEMT-Easy vector. Capped mRNA from *Xc-Myc-Mut*, wild-type *Xc-Myc*, *XSlug* (*Snail2*), *XTwist* and β -galactosidase were synthesized using the mMessage mMachine kit (Ambion).

Embryology and microinjections

Xenopus laevis embryos were generated and staged according to standard procedures (Sive et al., 2000). Knockdown experiments were performed by injecting embryos at the one-cell stage with 40 ng of *Xc-Myc* morpholino (Mo). Control morpholinos were injected at 40–80 ng per embryo. Following injections, embryos were visually inspected at the indicated stages of development until they reached stage 45, and were scored for the presence of edema. Embryos were stained with benzidine (Hemmati-Brivanlou and Thomsen, 1995) to visualize effects on *Xc-Myc* knockdown on blood development and the vascular system. For rescue experiments, 500 pg of *Xc-Myc-Mut*, *XSlug* or *XTwist* mRNA were mixed with 40 ng Mo and injected at the one-cell stage. Injections of wild-type *Xc-Myc* or β -galactosidase mRNA with Mo were used as controls. Embryos used for in situ hybridization were injected at the two-cell stage, in one blastomere, with half the dose of Mo (20 ng) or RNA (250 pg) mixed with mRNA encoding β -galactosidase to mark the injected side. At least three different batches of embryos obtained from different frogs were used for each set of experiments.

Lineage analysis was initially carried out at the 32-cell stage, yet here the morpholino dose proved toxic or failed to produce any phenotype at the lower doses tested. Therefore, lineage analysis was done at the 16-cell stage and provoked lineage-specific phenotypes. Following the fate maps of Moody (Moody, 1987), blastomeres of either the D2.1, V1.2 or V2.1 lineage were injected with a 1 nl mixture of rhodamine-dextran and either *Xc-Myc* morpholino (800 nM), or a combination of *XSlug* (266 nM) and *XTwist* (534 nM) morpholinos. The embryos were cultured overnight and sorted at stage 13 based on the presence of the rhodamine signal. Embryos which showed positive labeling were followed until stage 45 and scored for developmental defects including hemorrhage and edema. Lineage analyses were from different batches of embryos obtained from four different frogs.

Western blot analyses, whole-mount in situ hybridization and histology

Whole embryo extracts were prepared by Freon extraction and western blots were performed using a Myc antibody (Santa Cruz) that recognized *Xc-Myc* protein. In situ hybridization and β -galactosidase staining were performed according to standard methods (Sive et al., 2000). Digoxigenin-UTP-labeled antisense RNA probes were generated against *Xc-Myc*, *XTwist*, *XSlug* and *Xmsr* using MegaScript Kit (Ambion). All results were collected from two to four different batches of embryos obtained from different frogs.

For histology, staged embryos were fixed in MEMFA [0.1 M MOPS (pH 7.4), 2 mM EGTA, 1 mM MgSO₄, 3.7% formaldehyde] overnight at 4°C, dehydrated in a graded ethanol series and embedded in paraffin. Sections (4 μ m) were prepared and were stained with Hematoxylin and Eosin.

RESULTS

Xc-Myc is expressed in the primitive mesoderm and ventral blood islands that give rise to the vasculature

As a consequence of genome duplication during evolution (Bisbee et al., 1977), *Xenopus* harbors two copies of *Xc-Myc* (*Xc-Myc1* and *Xc-Myc2*), both of which are maternally expressed. However, only




Fig. 1. *Xc-Myc* expression and morpholino knockdown. (A) In situ hybridization of *Xc-Myc* expression during development. (i) Gastrula: expression in involuting mesoderm (M) that flanks the yolk plug. (ii) Neurula: expression in anterior region and in the lateral edges of neural crest (NC). (iii) Early tailbud: expression in the developing eye (E) and migratory neural crest cells (MNC). (iv) Tailbud (~stages 27/28): expression in eyes (E), brain (B), somites (S), pharyngeal arches (PA) and ventral blood islands (VBI). (v) Stage 35/36: expression is predominant in head and heart region (eyes, E; brain, B; heart, H; rostral lymph sac, RLS; aortic arches, AA). (B) The *Xc-Myc* morpholino blocks translation of *Xc-Myc*. In vitro translation of transcripts for wild-type (*Xc-Myc*) or a morpholino-resistant mutant (*Xc-Myc-Mut*) in the absence (–) or presence (+) of *Xc-Myc* morpholino (Mo) is shown. Control morpholinos were non-specific (A) or a scrambled *Xc-Myc* (B) morpholino. (C) Knockdown of *Xc-Myc* protein expression in vivo at different stages. Western blot of *Xc-Myc* expression in embryos injected with *Xc-Myc* morpholino (Mo); uninjected (uninj); loading control (input).

Xc-Myc1 is zygotically expressed following the mid-blastula transition (Vriz et al., 1989) (see Fig. S1 in the supplementary material). In the mouse embryo, Myc is expressed in endothelial-like (PECAM-1⁺) cells that line the blood islands of the yolk sac (Baudino et al., 2002), which give rise to both the embryonic vasculature and primitive hematopoietic cells. In *Xenopus*, the precursors of blood and vasculature arise in an analogous region coined the ventral blood island (Turpen, 1998). To define precisely the spatial and temporal patterns of *Xc-Myc* expression in *Xenopus* embryos, we performed whole-mount in situ hybridization (Fig. 1A). The probe was specific for *Xc-Myc* and does not recognize *XN-Myc*. During gastrulation, *Xc-Myc* is expressed in the area flanking the yolk plug corresponding to the involuting mesoderm (Fig. 1A, part i). Furthermore, during the neurula stages, *Xc-Myc* is expressed in the anterior, posterior and lateral edges of the embryo, as previously described (Bellmeyer et al., 2003). The latter region harbors pre-migratory and migratory neural crest precursors (Fig. 1A, parts ii,iii). At the tailbud stage, *Xc-Myc* expression was evident in the developing brain, eyes, somites, pharyngeal arches and, importantly, in the region corresponding to the ventral blood islands (VBI, Fig. 1A, part iv). By stage 35/36, *Xc-Myc* expression expanded into the region where the heart and outflow tract are formed and is strongly expressed in the rostral lymph sac (RLS, Fig.

1A, part v). Therefore, in addition to its known expression and role in neural crest development, *Xc-Myc* is also expressed in primitive mesoderm, in the VBI that gives rise to the vascular system, and in the rostral lymph sac, a crucial component of the lymphatic system.

***Xc-Myc* loss provokes massive edema and marked defects in organogenesis**

Given its early expression in primitive mesoderm, we assessed the potential role of *Xc-Myc* in vascular and blood development by knocking down *Xc-Myc* expression in one-cell stage embryos using morpholino oligonucleotides that were designed to block specifically translation of *Xc-Myc* mRNA (Fig. 1B). One-cell stage embryos were injected with a standard control morpholino, a scrambled *Xc-Myc* control morpholino or with the *Xc-Myc*-specific morpholino. The specificity and extent of the knockdown of *Xc-Myc* was assessed by western blot analysis. In vivo, the levels of *Xc-Myc* protein were drastically reduced in embryos injected with the *Xc-Myc*-specific morpholino compared with uninjected control embryos, and this was sustained from the neural tube (stages 19–21) through the tailbud stage (stage 32, Fig. 1C). Reduction of *Xc-Myc* at earlier stages (stage 10.5–11) was not detected (data not shown).

By contrast, *Xc-Myc* levels were unaffected by either of the two control morpholino oligonucleotides, as determined by in vitro translation (Fig. 1B). A successful phenotypic rescue of the *Xc-Myc* knockdown is presented in Fig. 5.

Knockdown of *Xc-Myc* did not lead to obvious external developmental abnormalities through stage 28 (see Fig. S2 in the supplementary material), although changes in gene expression were evident at this stage (see below, Fig. 4B). As expected (Bellmeyer et al., 2003), *Xc-Myc* morpholino-injected embryos showed craniofacial defects by stage 41 (Fig. 2A, Fig. 3A). However, in addition, we also observed obvious signs of ventral edema in *Xc-Myc*-knockdown embryos, and by stage 45 this edema was profound (Fig. 2A, white arrows). Cross-sections of embryos at stage 37 revealed marked defects in the development of the digestive tract that were associated with edema (Fig. 2B), as well as defects in the development of the somites and spinal cord, which were atrophied or missing in *Xc-Myc*-knockdown embryos (Fig. 2B). Furthermore, at stage 37 the hearts of *Xc-Myc* knockdown embryos lacked normal chambers (Fig. 2C) and large blood vessels such as the dorsal aorta and posterior cardinal vein appeared extremely thin (Fig. 2D, Fig. 3C). Therefore, knockdown of *Xc-Myc* in *Xenopus* leads to marked edema and associated catastrophic effects on organogenesis.

***Xc-Myc* knockdown impairs endothelial cell assembly into patent tubules**

We reasoned that many of the abnormalities observed during organogenesis and the massive edema in *Xc-Myc*-knockdown embryos might reflect a defective vasculature and/or lymphatic system. We ruled out one explanation for the source of edema, incomplete closure of the neural tube, as we found this step to be normal in *Xc-Myc*-knockdown embryos (data not shown). At the stages of embryonic development affected, blood vessels are composed exclusively of endothelial cells and pericytes, which are derived from mesoderm and neural crest progenitors, respectively (Etchevers et al., 2001; Cox et al., 2006). To determine whether vascular endothelial cells were correctly specified and/or assembled in *Xc-Myc*-depleted embryos, we assessed the effects of *Xc-Myc* knockdown on the expression of the embryonic endothelial lineage marker *Xenopus mesenchyme-associated serpentine receptor* [*X-msr*] (Devic et al., 1996).

Whole-mount in situ hybridization showed a reduced and more diffuse staining pattern for *X-msr* in *Xc-Myc* knockdown stage 37 embryos compared with uninjected embryos. This was especially evident in the blood vessels of the head region, including the aortic arches and the anterior cardinal vein, as well as in the vitelline vein network (Fig. 3A,B). The vasculature surrounding the lens (tunica vasculosa lentis) and the developing retina (choroid) was also incomplete and/or collapsed (Fig. 3A,B). One of the most telling defects was in the rostral lymph sac (RLS), which appeared completely missing. Normally this distinct structure, found just anterior to the heart region, strongly expresses *X-msr* (Fig. 3B) (Ny et al., 2005). This sac is composed of endothelial cells derived from a common endothelial precursor that also gives rise to vascular progenitors originating in the lateral plate mesoderm (Ny et al., 2005). In *Xc-Myc*-depleted embryos *X-msr* staining is essentially absent in this region (Fig. 3B, arrowhead). Therefore, the *Myc* knockdown phenotype also includes defects in lymphatic vessel development.

In most cases, the endothelial cells detected by *X-msr* expression in *Xc-Myc* knockdown embryos appeared to align in a roughly normal vascular pattern, yet their staining was much weaker and was




Fig. 2. Knockdown of *Xc-Myc* provokes edema and compromises organogenesis. (A) Embryos injected with *Xc-Myc* morpholino (*Xc-Myc Mo*) at the one-cell stage developed edema in the head and heart region (white arrows). By stage 45 (right panels) massive edema and associated defects in organogenesis were obvious in *Xc-Myc* knockdown tadpoles (*Xc-Myc Mo*). (B–D) Histological analysis (stage 37) of *Xc-Myc* knockdown embryos revealed profound developmental defects: somites (S), spinal cord (SC), notochord (N), abdominal cavity (ac), heart (H), pronephros (PN), dorsal aorta (DA) and cardinal vein (CV). (C) The heart is shown. (D) The region containing the dorsal aorta and cardinal vein.




Fig. 3. *Xc-Myc* knockdown impairs endothelial cell development. (A,B) Whole mount in situ hybridization (stage 37) for endothelial lineage marker *X-msr*; (B) enlargement of the embryos shown in A. *X-msr* staining is reduced and diffuse in *Xc-Myc* knockdown embryos throughout, and the vitelline vein network (vvn), aortic arches (aa), tunica vasculosa lentis (tv), anterior cardinal vein (acv) and rostral lymph sac (RLS) are reduced or missing. H, heart; pcv, posterior cardinal vein; isv, intersegmental vessels. (C) Histology of posterior cardinal vein (pcv) and dorsal aorta at stage 37. Uninj, uninjected control; *Xc-Myc* Mo, *Xc-Myc* morpholino-injected embryos. The vessels found in *Xc-Myc* morpholino-injected embryos have remarkably thin walls and empty lumens. Analyses based on five or six embryos from two different experiments.

often diffuse (Fig. 3A,B). Indeed, this was confirmed by detailed histological analyses of the posterior cardinal vein and the dorsal aorta, which revealed that endothelial linings of these major blood vessels were very thin and appeared to be composed of fewer endothelial cells (Fig. 3C).

Xc-Myc* is essential for normal vascular development in *Xenopus

To assess the status and function of the hematopoietic and vascular system in *Xc-Myc*-depleted embryos, we initially stained erythrocytes at stage 45 with benzidine, which stains red blood cells and thus allows visualization of the entire circulatory system (Hemmati-Brivanlou and Thomsen, 1995). Benzidine staining revealed that tadpoles injected with control morpholinos had a well-developed vasculature, including the aortic arches emanating from the heart (Fig. 4A). In *Xc-Myc*-knockdown tadpoles, blood was also evident; therefore, there are no obvious effects of *Xc-Myc* loss on erythrocyte development. However, the blood was pooled and localized in hemorrhagic areas in different regions of the body proper in *Xc-Myc*-depleted embryos, most often in the abdominal cavity (Fig. 4A). Moreover, in most of the *Xc-Myc*-knockdown embryos, the aortic arches and peripheral vessels in the tail were not stained by benzidine, indicating that blood had leaked from the vasculature. Indeed, quantification of these phenotypes




Fig. 4. Edema provoked by *Xc-Myc* knockdown is associated with massive hemorrhage and impaired expression of *X-ERG*, *Scl* and *Prox1*. (A) The vascular networks of uninjected (Uninj) and *Xc-Myc* morpholino (Mo)-injected embryos were visualized by staining blood cells with benzidine. Hemorrhagic areas are present throughout body proper of Mo-injected embryos. H, heart; aa, aortic arches; vvn, vitelline vein network; pcv, posterior cardinal vein; da, dorsal aorta. (B) The effects of *Xc-Myc* knockdown on the expression of genes involved in vascular development was assessed by qRT-PCR in control (dark blue bars) and *Xc-Myc* morpholino-injected (light blue bars) embryos at stage 28. Expression was normalized to *Gapdh*.

demonstrated that ~85% of *Xc-Myc* morpholino-injected stage 45 embryos had profound edema (Fig. 5A, $n=339$) and that nearly all of these ($n=316$) had associated defects in vessel development (Fig. 5B, part ii; Fig. 5C), clearly linking these two events. By contrast, fewer than 5% of uninjected embryos ($n=617$) or embryos injected with a scrambled control *Xc-Myc* morpholino ($n=190$) showed edema and vascular defects (Fig. 5A,B, part i; Fig. 5C).

Defects in vascular development in *Xc-Myc*-knockdown embryos were observed well before edema became obvious at stages 40/41. For example, although blood could be observed throughout the circulatory system of control embryos, it was largely absent in the peripheral circulatory system of *Xc-Myc* morpholino-injected stage 37 embryos (Fig. 3B).

To confirm that the developmental defects provoked by the *Xc-Myc* morpholino were not due to off-target effects, embryos were co-injected with the *Xc-Myc* morpholino and mRNA encoding a wobble mutant of *Xc-Myc* (*Xc-Myc*-Mut) designed to block its recognition by the *Xc-Myc* morpholino. Indeed, in vitro translation of *Xc-Myc*-Mut protein was unaffected by the *Xc-Myc* morpholino (Fig. 1B). Importantly, all of the defects that were manifest in *Xc-Myc* knockdown embryos, including edema ($n=327$) and vascular defects ($n=240$), were rescued by co-injection of mRNA encoding the mutant of *Xc-Myc* (Fig. 5A,B, part iii; Fig. 5C).




Fig. 5. Edema provoked by Xc-Myc knockdown is intrinsic and specific and Xc-Myc overexpression induces ectopic vascular beds. (A) The percentage of Xc-Myc morpholino-injected embryos that developed edema (light blue bars) or appeared normal (dark blue bars) is shown. Co-injection of Xc-Myc-Mut rescued the edema phenotype. (B) Representative images of stage 45 control (i) or those injected with Xc-Myc morpholino (ii), with both Xc-Myc-Mut mRNA and Xc-Myc morpholino (iii) [note rescue of phenotype and hypervascularization (black arrows)], or with Xc-Myc RNA (iv), showing hypervascularization and ectopic vascular beds (black arrows). (C) The percentage of Xc-Myc morpholino-injected embryos with hemorrhage. Co-injection of Xc-Myc-Mut mRNA rescued the phenotype. Injection of either wild-type Xc-Myc or mutant Xc-Myc-Mut mRNA induced hypervascularization (red bars).

In addition to ameliorating the edema and vascular phenotypes of Xc-Myc knockdown embryos, overexpression of Xc-Myc-Mut often led (in 55% of injected embryos) to abnormal patterns of blood distribution, which were characterized by ectopic vascular beds and hypervascularization (Fig. 5B, part iii, black arrows; Fig. 5C, red bars, $n=240$). Furthermore, 70% of embryos injected with wild-type Xc-Myc mRNA alone displayed an ectopic formation of blood vessels (Fig. 5B, part iv, black arrows; Fig. 5C, red bars, $n=146$), consistent with findings in mice that have demonstrated Myc overexpression can provoke angiogenesis (Pelengaris et al., 1999; Knies-Bamforth et al., 2004). Therefore, physiological thresholds of Myc are essential for normal formation of patent vessels during vasculogenesis.

Xc-Myc is required for the normal expression of *Egr*, *Scl* and *Prox1*

To assess whether the defects in vessel development of the vascular and lymphatic systems caused by Myc knockdown were associated with specific deficits in the expression of key regulators of vasculogenesis or lymphangiogenesis, we analyzed the expression of *Vegf* and its receptor *Flk1*, which are important for the initial steps of differentiation of angioblasts into endothelial cells. We also examined expression of the angiopoietin receptor *Tie2*, which regulates the recruitment and migration of smooth muscle cells and pericytes that cover newly forming blood vessels (Rossant and Howard, 2002; Carmeliet, 2003; Cleaver and Melton, 2003; Cleaver, 2004). In addition, we assessed the expression of *X-erg*, an Ets family transcription factor that is expressed in vascular endothelial

cells, in the neural crest-derived mesenchymal cells of pharyngeal arches, and in the endocardium. *X-erg* is thought to direct cell migration during vascular development (Remy and Baltzinger, 2000; Tahtakran and Selleck, 2003). Although *Vegf*, *Flk1* and *Tie2* expression changed little in Xc-Myc knockdown embryos, *X-erg* expression was reduced by ~50% (Fig. 4B).

Additional transcriptional regulators of vasculogenesis and lymphangiogenesis include the transcription factors *Scl*, which plays critical roles in yolk sac erythropoiesis and in angiogenic remodeling of the yolk sac capillaries into complex vitelline vessels (Mead et al., 1998), and *Prox1*, a master regulator of lymphangiogenesis (Wigle and Oliver, 1999; Wigle et al., 2002). Notably, knockdown of Xc-Myc led to marked reductions in the expression of both *Scl* and *Prox1* (Fig. 4B). Like *X-erg*, reduced levels of *Scl* and *Prox1* would be predicted to contribute to the edematous phenotype of Xc-Myc knockdown embryos, which displayed marked defects in the ventral vascular plexus and rostral lymph sac.

A Myc-to-Slug/Twist pathway directs vasculogenesis and lymphangiogenesis

Knockdown of Myc in *Xenopus* results in the loss of neural crest derivatives, such as craniofacial structures, cartilage and fins, and compromises the expression of the *Slug* and *Twist* transcription factors in the neural crest. Indeed, *Slug* and *Twist* are also important for cell fate determination and migration of the neural crest and function downstream of Xc-Myc (LaBonne and Bronner-Fraser, 2000; Bellmeyer et al., 2003). However, *Slug* and *Twist* are also expressed in the lateral plate mesoderm, which generates endothelial precursor cells (Hopwood et al., 1989; Mayor et al., 1995). This suggested that *Slug* and/or *Twist* might also function downstream of Xc-Myc to coordinate normal blood and lymph vessel development. As expected, injection of Xc-Myc morpholino into one cell of a two-cell embryo disrupted the expression of *Twist* and *Slug* on the injected side, and these defects were rescued by the co-injection with the mRNA encoding the wobble mutant of Xc-Myc (see Fig. S3 in the supplementary material). Furthermore, co-injection of Xc-Myc morpholino and *Slug* or *Twist* mRNA into one cell of two-cell embryos rescued defects in endogenous *XSlug* or *XTwist* expression (see Fig. S3 in the supplementary material). Therefore, either *XSlug* or *XTwist* can function downstream of Myc.

To test the potential functions of *XSlug* or *XTwist* downstream of Myc in vessel development, one-cell embryos were co-injected with Xc-Myc morpholino and *Slug* or *Twist* mRNAs, and assessed at stage 45 by staining with benzidine. Notably, many embryos injected with Xc-Myc morpholino together with *Slug* ($n=181$) or *Twist* ($n=242$) mRNA did not develop edema or hemorrhage, a hallmark of those injected with the Xc-Myc morpholino alone (Fig. 6A,B, $n=316$). Rescue of this phenotype was specific for *Slug* or *Twist* mRNA, as embryos co-injected with the Xc-Myc morpholino and β -galactosidase mRNA ($n=169$) displayed profound defects in vascular development (Fig. 6A). Indeed, *Slug* or *Twist* mRNA/Xc-Myc morpholino co-injected embryos ($n=327$) were phenotypically similar to normal embryos and to those rescued by co-injection of the wobble Xc-Myc-Mut mRNA ($n=108$, Fig. 6A,B). However, *Slug*- or *Twist*-injected embryos lacked the hyper-vascularization phenotype that characterized Xc-Myc overexpression (Fig. 5B,C). Therefore, enforced expression of either *Slug* or *Twist* can specifically rescue the defects in vessel development provoked by Xc-Myc knockdown.

To investigate more directly what cell lineage Xc-Myc, *XTwist* and *XSlug* were acting through to affect vessel development, we injected their corresponding morpholinos together with a lineage

tracer into blastomeres of the 16-cell stage embryo whose descendants mostly contribute to either neural crest or lateral plate mesoderm. Both *XTwist* (Hopwood et al., 1989) and *XSlug* (Mayor et al., 1995) are expressed in lateral plate mesoderm. The V1.2 blastomeres are a major contributor to both trunk and head neural crest, whereas D2.1 mostly to head neural crest and lateral plate mesoderm. V2.1 contributes mostly to lateral plate mesoderm and nothing to head neural crest (Fig. 7A,B) (Moody, 1987). Specifically, descendants of the D2.1 lineage give rise to embryonic blood, endocardium and endothelial cells that comprise the ventral aorta and vitelline veins, whereas V2.1 descendants give rise to blood precursor cells and endothelial cells of major blood vessels (Walmsley et al., 2002). Notably, *Xc-Myc* or *XSlug/XTwist* knockdown within the neural crest lineage (V1.2 or D1.2) did not result in edema (0%, $n=41$; 0%, $n=29$) and very few (3%, $n=41$; 7%, $n=29$) developed hemorrhagic spots (compare Fig. 7B,C, V1.2, controls with Fig. 4A). In sharp contrast, *Xc-Myc* morpholino injections into D2.1 (lateral plate mesoderm) resulted in 44% edematous and 54% hemorrhagic embryos ($n=57$, Fig. 7B). Similar results were obtained for the *XSlug/XTwist* MO D2.1 injections (33%, 33%, $n=18$) with most embryos displaying both phenotypes (Fig. 7B,C). Interestingly, knockdown of *Xc-Myc* or *XSlug/XTwist* in the posterior lateral plate mesoderm (V2.1) was sufficient to cause edema in the head (33%, $n=15$) and edematous or hemorrhagic areas throughout the embryo (66%, $n=15$; and 75%, $n=12$). These findings

are inconsistent with a cell-autonomous effect of *Xc-myc*, *XSlug* or *XTwist* in the neural crest lineage for vascular development. Furthermore, a lack of benzidine staining of the brachial arches, heart and outflow tract was also observed in the posterior lateral plate mesoderm targeted knockdowns (Fig. 7B,C). Collectively, these findings show that *Xc-Myc* and *XSlug/XTwist* operate in a regulatory pathway outside of the neural crest lineage, but within the lateral plate mesoderm, to affect both the endothelial and blood lineages.

Interestingly, although *Xc-Myc* expression precedes *Slug*, morpholino-induced knockdown of *Slug* also affected *Xc-Myc* expression (Fig. 6C, parts i-iii, $n=11$). Indeed, almost 90% of *Slug* morpholino-injected embryos showed effects on *Xc-Myc* expression in the somites, eye region and neural crest (Fig. 6C). Furthermore, although neural crest cells expressing *Xc-Myc* were affected by *Slug* knockdown, the vascular defects evident following *Xc-Myc* knockdown were never observed (Fig. 6C, part iv,v). Therefore, although *Slug* is sufficient to rescue the effects of knockdown of *Myc* on vessel development, loss of *XSlug* alone is not sufficient to disrupt vascular integrity, but also required loss of *XTwist*. These results indicate a level of functional redundancy downstream of *Myc* in this pathway.

DISCUSSION

Myc oncoproteins are required for cell growth and cell cycle traverse in most (but not all) tissue types. Accordingly, here we have shown that *Xc-Myc* is also required for normal vessel development. The pathway by which *Xc-Myc* regulates this process is, however, complex, where *Xc-Myc* functions are specifically required for endothelial cells to assemble into patent vessels during both vasculogenesis and lymphangiogenesis. Here, *Xc-Myc* is required for normal expression of *Erg*, *Scl* and *Prox1*, transcription factors that regulate vascular and lymphatic development (Mead et al., 1998; Wigle and Oliver, 1999; Wigle et al., 2002; Tahtakran and Selleck, 2003). Furthermore, *Slug* and *Twist*, transcription factors that function downstream of *Myc* in neural crest development (Bellmeyer et al., 2003), are shown here to also function downstream of *Myc* in directing normal vessel development within the lateral plate lineage, a site where both genes are also expressed (Mayor et al., 1995; Hopwood et al., 1989). Given the observed effects of knockdown of *Slug* on the expression of *Xc-Myc*, the ability of *Slug* or *Twist* to rescue the phenotypes manifest following *Xc-Myc* knockdown, and the ability of *XSlug/XTwist* morpholinos to cause vascular defects similar to *Xc-Myc* knockdowns, these findings support a model whereby *Myc*, *Twist*, and *Slug* function in a regulatory circuit that also directs the maturation of vessels of the vascular and lymphatic systems (Fig. 8).

Myc is required for normal vessel development in *Xenopus*

In the mouse, *Myc* appears required for primitive erythropoiesis and vasculogenesis (Baudino et al., 2002). In our studies, *Xc-Myc* was not fully depleted until the neural tube stage (stage 21), leaving open the possibility for an earlier role for *Xc-Myc* in the specification of endothelial progenitors. Maternal *Xc-Myc* is present at high levels in the unfertilized egg and could provide a source of this protein to the early embryo (Vriz et al., 1989). However, loss of *Xc-Myc* by stage 21 provokes massive hemorrhage and edema, which are indicative of vascular defects. *Xc-Myc*-depleted embryos displayed very thin vessels that were generally devoid of blood cells, which apparently had leaked out and pooled in the embryo body proper. These phenotypes were intrinsic to *Myc*. As progenitors for blood




Fig. 6. *Slug* or *Twist* rescue the vascular defects provoked by *Xc-Myc* knockdown. (A) The percentage of embryos that appeared normal (dark-blue bars) or showed edema associated with hemorrhage (light-blue bars) after injection of *Xc-Myc* morpholino alone or mixed with *Xc-Myc-Mut*, wild-type *Xc-Myc*, *Slug*, *Twist* or β -galactosidase mRNAs. (B) Representative images of the results in A, showing the rescue of the *Xc-Myc* knockdown phenotype by *Slug* or *Twist*. (C) One blastomere of a two-cell stage embryo was injected with *Slug* morpholino. In situ hybridization at the neural tube stage using a probe specific for *Xc-Myc* showed that knockdown of *Slug* indeed affects *Xc-Myc* expression in the region corresponding to the neural crest (i-iii). On the injected side (black arrowheads) an accumulation of *Xc-Myc*-expressing cells is evident, while on the uninjected side cells expressing *Xc-Myc* have started to migrate (red arrow). A deviation in the body axis is also evident (ii,iii). Despite affecting *Xc-Myc* expression during neurulation, knockdown of *Slug* in two-cell embryos is not sufficient to cause the edema and hemorrhagic phenotype (iv,v), as observed upon *Xc-Myc* knockdown using *Xc-Myc* morpholino.




Fig. 7. Xc-Myc or XSlug/XTwist targeted knockdown in lateral plate mesoderm but not the neural crest lineage, provokes edema and hemorrhage. (A) Map showing the blastomeres targeted for knockdown of *Xc-Myc* or *XSlug/XTwist* in predominantly neural crest (V1.2) or lateral plate mesoderm precursors (D2.1 or V2.1). Correct targeting of the morpholinos is shown in the next three images taken at neurula and tailbud when neural crest cells start migrating. NC, neural crest; LPM, lateral plate mesoderm; Neph, nephrotome. (B,C) Embryos were injected with a mixture of either *Xc-Myc* morpholino (B) or *XSlug/XTwist* morpholino (C), and were dextran fluorescently labeled with rhodamine. At stage 43, embryos were stained with benzidine to reveal the location of blood. Knockdown of *Xc-myc* or *XSlug/XTwist* within the lateral plate mesoderm (3rd and 4th column), but not the neural crest (2nd column), provoked edema (arrows) and hemorrhagic (arrowheads) phenotypes. Levels of blood in the V2.1 injected embryos (4th column) are significantly lower (dashed arrow).

and endothelial cells first appear just posterior to the cement gland and in the lateral plate mesoderm at the neurula stages (Walmsley et al., 2002; Cleaver, 2004), we infer that these progenitors, and the lymphangioblasts and endothelial cells that arise from them (Ny et al., 2005), require *Xc-Myc* to mature and form patent fully functional vessels. Conversely, we also infer that the hypervascularization phenotype observed in embryos injected with *Xc-Myc* mRNA may be due to increases in numbers of angioblasts and/or their progeny, which results in the production of excess vessels, a phenotype that is akin to those observed following ectopic expression of *Vegf* in *Xenopus* (Cleaver, 2004).

In the *Myc* knockout mouse embryo there appear to be defects in the expression of regulators necessary for initiation of the vasculogenesis program, in particular in the expression of *Vegf* and its receptors *Flk1* and *Flt1* (Baudino et al., 2002). By contrast, in *Xenopus*, in situ hybridization and histological analyses revealed that many of the early steps in vasculogenesis occurred normally in *Xc-Myc* knockdown embryos, including the specification of endothelial cell precursors (angioblasts), their migration and coalescence into continuous strands of endothelial cells at correct locations in the embryo, and proper expression of *Vegf* and *Flk1*. Thus, given that *Xc-Myc* is expressed in the lateral plate mesoderm and VBI where angioblasts form, these developmental steps are either independent of *Xc-Myc*, or occur before effective MO *Xc-Myc* knockdown at stage 21.




Fig. 8. A Myc-Slug/Twist regulatory circuit directs vasculogenesis and lymphangiogenesis. *Xc-Myc* is required for the normal expression of the *XSlug* and *XTwist* transcription factors, either of which are sufficient to rescue the defects in vascular and lymphatic development provoked by knockdown of *Xc-Myc*. Knockdown of *XSlug* also disrupts normal patterns of *Xc-Myc* expression, indicating a positive-feedback loop. Knockdown of both *XSlug* and *XTwist* in lateral plate mesoderm, but not neural crest, results in the vascular defects observed after knockdown of *Xc-Myc*, indicating both genes operate in the same pathway and downstream of *Myc*. Either ectopic *Slug* or *Twist* rescue defects in endogenous *XSlug* or *XTwist* expression induced by *Xc-Myc* knockdown, indicating that they also regulate each the expression of one another.

Xc-Myc is required in endothelial cells for vessel maturation

Xc-Myc may regulate *Xenopus* vascular development at different levels. First, the numbers of endothelial cells may be reduced in *Xc-Myc* knockdown embryos, suggesting at least a partial role for *Xc-Myc* in the early expansion of this cell lineage. Interestingly, Bellmeyer et al. (Bellmeyer et al., 2003) ruled out a role for *Xc-Myc* in proliferation within the neural crest lineage. Although we were unable to detect obvious differences in cell proliferation after knockdown of *Xc-Myc* using histone markers for proliferation (data not shown), *Xc-Myc* has been reported to regulate cell proliferation in *Xenopus* (Etard et al., 2005). Second, as endothelial cells assemble into tubes later in development, they may fail to form normal intercellular junctions following *Xc-Myc* knockdown, resulting in inadequate sealing. Third, smooth muscle cells or pericytes may fail to recruit to endothelial tubes, which would also result in leaky vessels. The latter hypothesis was appealing given the involvement of *Myc* in neural crest specification in *Xenopus* (Bellmeyer et al., 2003) and the contribution of neural crest cells to smooth muscle and pericytes in the cardiovascular system (La Bonne and Bronner-Fraser, 1999; Huang and Saint-Jeannet, 2004). However, our data support endothelial cells as the crucial target as we observed leaky vessels devoid of red blood cells by stage 37, a time prior to the recruitment of smooth muscle cells and pericytes to vessels (Warkman et al., 2005; Cox et

al., 2006). In addition, Xc-Myc-depleted embryos lacked a distinct rostral lymph sac (Fig. 3B), a structure comprised only of endothelial cells that are held together by desmosomal-like structures (Ny et al., 2005). Collectively, these observations are therefore most consistent with Xc-Myc-depleted embryos being defective in endothelial numbers and cell-cell adhesion, rather than in mural cell recruitment. Together with our lineage studies, these results further support a role for Xc-Myc in vascular development independent of the neural crest. However, as neural crest cells migrate over the mesoderm, we cannot rule out that perturbing mesodermal lineages does not also affect neural crest migration, although we can rule out a cell-autonomous effect of c-Myc on the neural crest lineage in vascular development.

The Myc-Slug/Twist regulatory circuit

Slug and Twist perform important developmental roles as mediators of the epithelial-to-mesenchymal transition by regulating the expression of cell-adhesion molecules such as V-cadherin (Bolos et al., 2003; Marin and Nieto, 2004), which are also regulated indirectly by Myc through Slug (Wilson et al., 2004). More recently, Twist and Slug have been suggested to play crucial roles in cancer and tumor angiogenesis, processes that are also regulated by Myc (Pelengaris et al., 1999; Baudino et al., 2002; Valsesia-Wittmann et al., 2004; Elloul et al., 2005; Yang et al., 2006). Slug and Twist have well described roles in neural crest development in *Xenopus* but have never been associated with vascular development in this organism (LaBonne and Bronner-Fraser, 1999; LaBonne and Bronner-Fraser, 2000; Huang and Saint-Jeannet, 2004). Notably, Xc-Myc knockdown disrupted the normal expression of *Slug* and *Twist* (data not shown), and ectopic Twist or Slug were able to rescue the vascular defects of Xc-Myc knockdown embryos. Moreover, Slug knockdown affected the expression and/or migration of Xc-Myc-expressing cells, indicating a feedback loop in this regulatory circuit (Fig. 8). However, knockdown of XSlug alone did not elicit vascular defects, but an XSlug/XTwist dual knockdown did reveal redundancy in this pathway (Fig. 7B,C). Collectively, these findings support a model whereby Myc, Twist and Slug also function in a regulatory circuit that directs vasculogenesis and lymphangiogenesis outside the neural crest lineage (Fig. 8).

We propose that endothelial cell-cell interactions are directed by Xc-Myc. Also consistent with this model, we found that Xc-Myc depletion compromised the expression of *Scl*, which directly induces the expression of vascular endothelial (VE)-cadherin (Deleuze et al., 2007). Notably, VE-cadherin is an essential adhesion factor at intercellular junctions important in the patency of blood and lymph vessels (Ny et al., 2005). Therefore, Myc, together with Slug and/or Twist, may regulate the assembly of blood vessels by directing the expression of these crucial adhesion receptors. Future studies will explore these models of Myc function.

We thank Dr Robert N. Eisenman for providing the Xc-Myc cDNA, Dr Paul Krieg for the *X-msr* and *ERG* cDNA, Dr Amar Singh for advice, and Dr Paul Mead for providing the β -galactosidase expression construct and for invaluable guidance. This work was supported by NIDDK R01 grant DK44158 (J.L.C.), by NIGMS R01 grant GM33932 (M.L.K.), by the Cancer Center (CORE) support grant CA21765, and by the American Lebanese Syrian Associated Charities (ALSAC) of St Jude Children's Research Hospital.

Supplementary material

Supplementary material for this article is available at <http://dev.biologists.org/cgi/content/full/135/11/1903/DC1>

References

Baudino, T. A., McKay, C., Pendeville-Samain, H., Nilsson, J. A., Maclean, K. H., White, E. L., Davis, A. C., Ihle, J. N. and Cleveland, J. L. (2002). c-Myc is

- essential for vasculogenesis and angiogenesis during development and tumor progression. *Genes Dev.* **16**, 2530-2543.
- Bellmeyer, A., Krase, J., Lindgren, J. and LaBonne, C. (2003). The protooncogene c-Myc is an essential regulator of neural crest formation in *Xenopus*. *Dev. Cell* **4**, 827-839.
- Bernard, S. and Eilers, M. (2006). Control of cell proliferation and growth by Myc proteins. *Results Probl. Cell Differ.* **42**, 329-342.
- Bisbee, C. A., Baker, M. A., Wilson, A. C., Hadj-Hazimi, I. and Fischberg, M. (1977). Albumin phylogeny for clawed frogs (*Xenopus*). *Science* **195**, 785-787.
- Bolos, V., Peinado, H., Perez-Moreno, M. A., Fraga, M. F., Esteller, M. and Cano, A. (2003). The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. *J. Cell Sci.* **116**, 499-511.
- Carmeliet, P. (2003). Angiogenesis in health and disease. *Nat. Med.* **9**, 653-660.
- Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoek, A., Harpal, K., Eberhardt, C. et al. (1996). Abnormal blood vessel development and lethality in embryos lacking a single *Vegf* allele. *Nature* **380**, 435-439.
- Cleaver, O. (2004). Blood vessel signals during development and beyond. *Curr. Top. Dev. Biol.* **62**, 1-36.
- Cleaver, O. and Melton, D. A. (2003). Endothelial signaling during development. *Nat. Med.* **9**, 661-668.
- Cox, C. M., D'Agostino, S. L., Miller, M. K., Heimark, R. L. and Krieg, P. A. (2006). Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. *Dev. Biol.* **296**, 177-189.
- Davis, A. C., Wims, M., Spotts, G. D., Hann, S. R. and Bradley, A. (1993). A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. *Genes Dev.* **7**, 671-682.
- de Alboran, I. M., O'Hagan, R. C., Gartner, F., Malynn, B., Davidson, L., Rickert, R., Rajewsky, K., DePinho, R. A. and Alt, F. W. (2001). Analysis of c-MYC function in normal cells via conditional gene-targeted mutation. *Immunity* **14**, 45-55.
- Deleuze, V., Chalhoub, E., El-Hajj, R., Dohet, C., Le Clech, M., Couraud, P. O., Huber, O. and Mathieu, D. (2007). TAL-1/SCL and its partners E47 and LMO2 up-regulate VE-cadherin expression in endothelial cells. *Mol. Cell. Biol.* **27**, 2687-2697.
- Devic, E., Paquereau, L., Vernier, P., Knibiehler, B. and Audigier, Y. (1996). Expression of a new G protein-coupled receptor X-msr is associated with an endothelial cell lineage in *Xenopus laevis*. *Mech. Dev.* **59**, 129-140.
- Elloul, S., Elstrand, M., Nesland, J. M., Tropé, C., Kvalheim, G., Goldberg, I., Reich, R. and Davidson, B. (2005). Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. *Cancer* **103**, 1631-1643.
- Etard, C., Gradi, D., Kunz, M., Eilers, M. and Wedlich, D. (2005). Pontin and Reptin regulate cell proliferation in early *Xenopus* embryos in collaboration with c-Myc and Miz-1. *Mech. Dev.* **122**, 545-556.
- Etchevers, H. C., Vincent, C., Le Douarin, N. M. and Couly, G. F. (2001). The cephalic neural crest provides pericytes and smooth muscle cells to all blood vessels of the face and forebrain. *Development* **128**, 1059-1068.
- Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J. and Moore, M. W. (1996). Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. *Nature* **380**, 439-442.
- Fong, G. H., Rossant, J., Gerstenstein, M. and Breitman, M. L. (1995). Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. *Nature* **376**, 66-70.
- Grandori, C., Cowley, S. M., James, L. P. and Eisenman, R. N. (2000). The Myc/Max/Mad network and the transcriptional control of cell behavior. *Annu. Rev. Cell Dev. Biol.* **16**, 653-699.
- Hemmati-Brivanlou, A. and Thomsen, G. H. (1995). Ventral mesoderm patterning in *Xenopus* embryos: expression patterns and activities of BMP-2 and BMP-4. *Dev. Genet.* **17**, 78-89.
- Hopwood, N. D., Pluck, A. and Gurdon, J. B. (1989). A *Xenopus* mRNA related to *Drosophila twist* is expressed in response to induction in the mesoderm and neural crest. *Cell* **59**, 893-903.
- Huang, X. and Saint-Jeannet, J.-P. (2004). Induction of the neural crest and the opportunities of life on the edge. *Dev. Biol.* **275**, 1-11.
- Iritani, B. M. and Eisenman, R. N. (1999). c-Myc enhances protein synthesis and cell size during B lymphocyte development. *Proc. Natl. Acad. Sci. USA* **96**, 13180-13185.
- Johnston, L. A., Prober, D. A., Edgar, B. A., Eisenman, R. N. and Gallant, P. (1999). *Drosophila myc* regulates cellular growth during development. *Cell* **98**, 779-790.
- Knies-Bamforth, U. K., Fox, S. B., Poulson, R., Evan, G. I. and Harris, A. L. (2004). c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. *Cancer Res.* **64**, 6563-6570.

- LaBonne, C. and Bronner-Fraser, M.** (1999). Molecular mechanisms of neural crest formation. *Annu. Rev. Cell Dev. Biol.* **15**, 81-112.
- LaBonne, C. and Bronner-Fraser, M.** (2000). Snail-related transcriptional repressors are required in *Xenopus* for both induction of the neural crest and its subsequent migration. *Dev. Biol.* **221**, 195-205.
- Levine, A. J., Munoz-Sanjuan, I., Bell, E., North, A. J. and Hemmati-Brivanlou, A.** (2003). Fluorescent labeling of endothelial cells allows in vivo, continuous characterization of the vascular development of *Xenopus laevis*. *Dev. Biol.* **254**, 50-67.
- Marin, F. and Nieto, M. A.** (2004). Expression of chicken Slug and snail in mesenchymal components of the developing central nervous system. *Dev. Dyn.* **230**, 144-148.
- Mayor, R., Morgan, R. and Sargent, M. G.** (1995). Induction of the prospective neural crest of *Xenopus*. *Development* **121**, 767-777.
- Mead, P. E., Kelley, C., Hahn, P., Piedad, O. and Zon, L.** (1998). SCL specifies hemopoietic mesoderm in *Xenopus* embryos. *Development* **125**, 2611-2620.
- Mohun, T. J., Leong, L. M., Weninger, W. J. and Sparrow, D. B.** (2000). The morphology of heart development in *Xenopus laevis*. *Dev. Biol.* **218**, 74-88.
- Moody, S. A.** (1987). Fates of the blastomeres of the 16 cell-stage *Xenopus* embryo. *Dev. Biol.* **119**, 560-578.
- Nesbit, C. E., Tersak, J. M. and Prochownik, E. V.** (1999). Myc oncogenes and human neoplastic disease. *Oncogene* **18**, 3004-3016.
- Ny, A., Autiero, M. and Carmeliet, P.** (2005). Zebrafish and *Xenopus* tadpoles: small animal models to study angiogenesis and lymphangiogenesis. *Exp. Cell Res.* **312**, 684-693.
- Pelengaris, S., Littlewood, T., Khan, M., Elia, G. and Evan, G.** (1999). Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. *Mol. Cell* **5**, 565-577.
- Remy, P. and Baltzinger, M.** (2000). The Ets-transcription factor family in embryonic development: lessons from the amphibian and bird. *Oncogene* **19**, 6417-6431.
- Rossant, J. and Howard, L.** (2002). Signaling pathways in vascular development. *Annu. Rev. Cell Dev. Biol.* **18**, 541-573.
- Roussel, M. F., Cleveland, J., Shurtleff, S. A. and Sherr, C. J.** (1991). Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signaling. *Nature* **353**, 361-363.
- Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, F. X., Breitman, M. L. and Schuh, A. C.** (1995). Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice. *Nature* **376**, 62-66.
- Sive, H., Grainger, R. and Harland, R.** (2000). *Early Development of Xenopus laevis: A Laboratory Manual*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
- Tahtakran, S. A. and Selleck, M. A.** (2003). Ets-1 expression is associated with cranial neural crest migration and vasculogenesis in the chick embryo. *Gene Expr. Patterns* **3**, 455-458.
- Trumpp, A., Refaelli, Y., Oskarsson, T., Gasser, S., Murphy, M., Martin, G. R. and Bishop, J. M.** (2001). c-Myc regulates mammalian body size by controlling cell number but not size. *Nature* **414**, 768-773.
- Turpen, J. B.** (1998). Induction and early development of the hematopoietic and immune systems in *Xenopus*. *Dev. Comp. Immunol.* **22**, 265-278.
- Valsesia-Wittmann, S., Magdeleine, M., Dupasquier, S., Garin, E., Jallas, A. C., Combaret, V., Krause, A., Leissner, P. and Puisieux, A.** (2004). Oncogenic cooperation between H-Twist and N-myc overrides failsafe programs in cancer cells. *Cancer Cell* **6**, 625-630.
- Vriz, S., Taylor, M. and Mechali, M.** (1989). Differential expression of two *Xenopus c-myc* proto-oncogenes during development. *EMBO J.* **8**, 4091-4097.
- Walmsley, M., Ciau-Uitz, A. and Patient, R.** (2002). Adult and embryonic blood and endothelium derive from distinct precursor populations, which are differentially programmed by BMP in *Xenopus*. *Development* **129**, 5683-5695.
- Warkman, A. S., Zheng, L., Qadir, M. A. and Atkinson, B. G.** (2005). Organization and developmental expression of an amphibian vascular smooth muscle alpha-actin gene. *Dev. Dyn.* **233**, 1546-1553.
- Wigle, J. T. and Oliver, G.** (1999). Prox1 function is required for the development of the murine lymphatic system. *Cell* **98**, 769-778.
- Wigle, J. T., Harven, N., Detmar, M., Langutina, I., Grosveld, G., Gunn, M. D., Jackson, D. G. and Oliver, G.** (2002). An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. *EMBO J.* **21**, 1505-1513.
- Wilson, A., Murphy, M. J., Oskarsson, T., Kaloulis, K., Bettess, M. D., Oser, G. M., Pasche, A. C., Knabenhans, C., MacDonald, H. R. and Trumpp, A.** (2004). c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. *Genes Dev.* **18**, 2747-2763.
- Yang, J., Mani, S. A. and Weinberg, R. A.** (2006). Exploring a new Twist on tumor metastasis. *Cancer Res.* **66**, 4549-4552.